This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the potential of Centanafadine, a medication currently in development by Otsuka that has recently succeeded in registrational trials with children and teens for the treatment of ADHD
Ticker(s): OTSKYWho's the expert?
Institution: Self
- Board-certified psychiatrist based in the Echo Park neighborhood of Los Angeles
- Treats 80-100 active patients with GAD but have treated many more including when she worked in an anxiety specialty clinic
- Helps people with a variety of mental health conditions including but not limited to depression, anxiety, bipolar disorder, ADHD, obsessive compulsive disorder, and sleep issues
Interview GoalThis call will focus on the results rom the the registrational trials with children and teens for the treatment of ADHD with Centanafadine, a medication currently in development by Otsuka.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
